Yale Cancer Center

https://www.yalecancercenter.org/

 

Hematologic Oncology
31:13

ASH 2022 Conference Coverage

Selected Updates in MDS from ASH 2022

FEATURING Amer Zeidan
  • 70 views
  • February 14, 2023
48

Yale Cancer Center

Lecture Summary - The Importance of the TP53 Evaluation in the Management of HR-MDS

FEATURING Rory Shallis
  • 10 views
  • July 28, 2022
15:31

Yale Cancer Center

The Importance of the TP53 Evaluation in the Management of HR-MDS

FEATURING Rory Shallis
  • 37 views
  • July 15, 2022
07:27

Yale Cancer Center

ASCO 2021 Highlights on Treatment-Naïve Higher-Risk MDS: CR/OS Data From VERONA Study on Venetoclax With Azacitidine

FEATURING Amer Zeidan
  • 54 views
  • June 29, 2021
11:10

Yale Cancer Center

Yale Cancer Center Multiple Myeloma and Gammopathies: Translational Science With Clinical and Research Updates

FEATURING Natalia Neparidze
  • 115 views
  • April 13, 2021
  • 1
14:23

Yale Cancer Center

Translational Science in Myeloid Malignancies at Yale: Immunologic Approaches, IDH AML/MDS Program, Critical Unresolved Clinical Issues, Opportunities for Further Growth

FEATURING Thomas Prebet
  • 3 views
  • April 6, 2021
24:06

Yale Cancer Center

Post-Transplant Lymphoproliferative Disorders: WHO Classification, Epidemiology, Risk Factors, Timing, Prognosis & Treatment Options

FEATURING Francesca Montanari
  • 29 views
  • April 6, 2021
25:06

Yale Cancer Center

Mechanisms of B-Cell Selection as Therapeutic Targets in Leukemia and Lymphoma: Leveraging Mechanisms of Negative B-Cell Selection

FEATURING Markus Muschen
  • 3 views
  • April 6, 2021
16:29

Yale Cancer Center

B-Cell Selection as Therapeutic Targets in Leukemia and Lymphoma: Targeting Mechanisms of Negative B-Cell Selection

FEATURING Markus Muschen
  • 2 views
  • April 6, 2021
15:10

Yale Cancer Center

First Randomized Trial of Azacitidine w/ Durvalumab for the Front-Line Treatment of Older Pts with AML and MDS: Data Presented at ASH 2019

FEATURING Amer Zeidan
  • 354 views
  • March 25, 2020
  • 3
14:39

Yale Cancer Center

Safety, Efficacy, and Biomarker Analysis of a Phase 1 Study of PLK1 Onvansertib + Low-Dose Cytarabine or Decitabine in Relapsed/Refractory AML

FEATURING Amer Zeidan
  • 93 views
  • January 24, 2020
12:32

Yale Cancer Center

Safety and Efficacy of a Phase 1b Study of Venetoclax Monotherapy or in Combination With Azacitidine for the Treatment of Relapsed/Refractory MDS

FEATURING Amer Zeidan
  • 93 views
  • January 23, 2020